Sarepta Therapeutics (SRPT) Sees Wild Late-Day Action
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Wedbush Sees Sarepta Therapeutics (SRPT) Filing for Accelerated Approval of Eteplirsen
April 15, 2013 1:06 PM EDTWedbush reiterated its Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following two presentations at the World Orphan Drug Congress last week. Insight from the Congress suggests an accelerated approval filing of eteplirsen is likely, analysts led by Christopher N. Marai, Ph.D said.
"SRPT's main presentation focused on the potential regulatory path forward for follow-on compounds to treat DMD caused by mutations in rarer exons where running trials could be impractical," the Marai-led group... More
